Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events

Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Cloquet, Maarten Schram, Rutger Scharloo, Tim Boersma, Tim Stobernack, Pieter van Gelder
doi: https://doi.org/10.1101/2022.01.10.21268254
Bas Kolen
1Delft University of Technology, Delft, The Netherlands
2HKV lijn in water, Lelystad, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: b.kolen@hkv.nl
Laurens Znidarsic
1Delft University of Technology, Delft, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Voss
3Radboudumc, Nijmegen, The Netherlands
4Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Donders
5Breda University of Applied Sciences, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iris Kamphorst
5Breda University of Applied Sciences, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten van Rijn
5Breda University of Applied Sciences, Breda, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitri Bonthuis
6Fieldlab Program Committee, Zaandam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Merit Cloquet
6Fieldlab Program Committee, Zaandam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maarten Schram
6Fieldlab Program Committee, Zaandam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rutger Scharloo
6Fieldlab Program Committee, Zaandam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Boersma
6Fieldlab Program Committee, Zaandam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Stobernack
3Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieter van Gelder
1Delft University of Technology, Delft, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In response to the outbreak of SARS-CoV-2 many governments decided in 2020 to impose lockdowns. Although the package of measures which constitute such lockdowns differs between countries, it is a general rule that contacts between people, and especially in large groups of people, are avoided or prohibited. The main reasoning behind these measures is preventing that healthcare systems become overloaded. As of 2021 vaccines against SARS-CoV-2 are available, but these do not guarantee 100% risk reduction and it will take a while for the world to reach a sufficient immune status. This raises the question whether and under which conditions events like theater shows, conferences, professional sports events, concerts and festivals can be organized. The current paper presents a COVID-19 Risk taxation method for (large scale) events. This method can be applied to events to define an alternative package of measures replacing generic social distancing.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Click NL, see https://www.clicknl.nl/en/about-clicknl/

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human Research Ethics Committee TU Delft (http://hrec.tudelft.nl/) The application is approved by the Ethics Committee on the 4 December 2020. Contact persons: Ir. J.B.J. Groot Kormelink, secretary HREC Dr. Ir. U. Pesch Chair HREC Faculty of Technology, Policy and Management.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 10, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Cloquet, Maarten Schram, Rutger Scharloo, Tim Boersma, Tim Stobernack, Pieter van Gelder
medRxiv 2022.01.10.21268254; doi: https://doi.org/10.1101/2022.01.10.21268254
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 risk taxation model and validation based on large scale Dutch test-events
Bas Kolen, Laurens Znidarsic, Andreas Voss, Simon Donders, Iris Kamphorst, Maarten van Rijn, Dimitri Bonthuis, Merit Cloquet, Maarten Schram, Rutger Scharloo, Tim Boersma, Tim Stobernack, Pieter van Gelder
medRxiv 2022.01.10.21268254; doi: https://doi.org/10.1101/2022.01.10.21268254

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)